Clinical Trial Details
| Trial ID: | L4917 |
| Source ID: | NCT00593255 |
| Associated Drug: | Soluble Human Insulin |
| Title: | Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: soluble human insulin|DRUG: insulin aspart|DRUG: insulin NPH |
| Outcome Measures: | Primary: 2-hours postprandial plasma glucose (PPPG), after 12 weeks of treatment | Secondary: Percentage of subjects achieving 2-hours PPPG treatment target|Percentage of subjects achieving HbA1c treatment target|HbA1c|Fasting plasma glucose|Hypoglycaemic episodes |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 220 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2004-07 |
| Completion Date: | 2005-04 |
| Results First Posted: | |
| Last Update Posted: | 2016-12-22 |
| Locations: | Novo Nordisk Investigational Site, Beijing, Beijing, 100034, China|Novo Nordisk Investigational Site, Beijing, Beijing, 100101, China|Novo Nordisk Investigational Site, Beijing, Beijing, 100853, China|Novo Nordisk Investigational Site, Harbin, Heilongjiang, 150001, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, 200433, China |
| URL: | https://clinicaltrials.gov/show/NCT00593255 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|